ArticleFrontiers in public health2026
A patient journey map study on time toxicity among young and middle-aged patients with breast cancer.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Based on the journey map, this study identified the multidimensional real-world experiences and core pain points of time toxicity among young and middle-aged breast cancer patients throughout the entire disease course, to provide a reference for alleviating patients' time burden, optimizing the medical experience, and improving their quality of life. Methods: A descriptive qualitative study was conducted. From August 2025 to February 2026, purposive sampling was used to recruit 19 young and middle-aged patients with breast neoplasms undergoing treatment at a tertiary Class A hospital in Anhui Province. Data from semi-structured in-depth interviews were analyzed using conventional content analysis. Results: Participants experienced three sequential clinical phases including screening and diagnosis, treatment preparation, and treatment implementation. Their time toxicity experiences were categorized into four dimensions, namely behaviors, emotions, touchpoints and pain points, generating 19 phase-specific subthemes in total. Two cross-cutting core themes running through the full care pathway were further summarized from repeated shared experiences. Based on these findings, a patient journey map of time toxicity was developed for young and middle-aged patients with breast cancer. Conclusion: The experience of time toxicity in young and middle-aged breast cancer patients is dynamic and phase-specific. It is characterized by passive waiting and information asymmetry during screening; decision-making pressure, role transition, and time conflict during treatment preparation; and cumulative time costs and social role deprivation during treatment implementation. We recommend phased and precise intervention strategies to better balance survival benefits and quality of life in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.